IL6 and COVID-19: Targeting crucially involved molecules such as IL-6, and inhibiting signaling pathways involved in cytokine production appear to be promising approaches [41]; indeed, corticosteroids and IL-6 blockade (with tocilizumab or sarilumab) are now standard of care in patients with severe COVID-19 [41].